Showing results (2471-2480 of 2,573) with videos related to

Sort By:
Pageof 258
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysisMark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Plos One|February 4, 2014
Integrated genomic and epigenomic analysis of breast cancer brain metastasisBodour Salhia, Jeff Kiefer, Julianna T D Ross, et al.
Translational Oncology|April 29, 2014
Errors in Quantitative Image Analysis due to Platform-Dependent Image ScalingThomas L Chenevert, Dariya I Malyarenko, David Newitt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Cancer Discovery|August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front MutationsAlexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
JAMA Oncology|April 28, 2017
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular CancerBritt I Drögemöller, Jose G Monzon, Amit P Bhavsar, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
Cancer Discovery|February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II TrialGregory J Riely, Joel W Neal, D Ross Camidge, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 2, 2022
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis CCatrina M Loucks, Jennifer J Lin, Jessica N Trueman, et al.
Pageof 258